Global Recombinant DNA Technology

Recombinant DNA Technology Comprehensive Study by Application (Gene Therapy, Clinical Diagnosis, Insulin Production, Generate Antibody Probes, Others), End users Industry (Agriculture, Food Production, Human and Veterinary Medicine, Biotechnology, Pharmaceutical, Other), Technique (CRISPR-Cas9, Polymerase Chain Reaction (PCR, DNA Sequencing, Gene Cloning) Players and Region - Global Market Outlook to 2030

Recombinant DNA Technology Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Recombinant DNA Technology
Recombinant DNA technology is a laboratory technique in which DNA molecules from different species are joined together and inserted into a host organism to produce a new genetic combination. There are a wide variety of advantages to rDNA, including increased resistance of crop plants to harsher environmental conditions or pests, innovative medical and pharmaceutical research to develop new therapeutics, the development and insertion of DNA therapeutics (gene therapies) into damaged chromosomes to treat hereditary diseases, and many more. Continuous advancements in molecular biology techniques and genetic engineering tools have enhanced the efficiency and precision of recombinant DNA technology. This has led to the development of new and improved products and processes, fostering market growth.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The market for recombinant DNA technology is dynamic and characterized by ongoing research and development, mergers and acquisitions, and collaborations. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

F. Hoffmann-La Roche Ltd (Switzerland), Biogen (United States), Amgen Inc. (United States), Novartis AG (Switzerland), Genentech, Inc. (United States), DAIICHI SANKYO COMPANY, LIMITED. (Japan), 4basebio (United Kingdom), Profacgen (United States), Astellas Pharma Inc. (Japan), Sanofi (France), Pfizer Inc. (United States), Bioclone Inc. (Brazil), AstraZeneca (United Kingdom), Takeda Pharmaceutical Company Limited (Japan), LenioBio (Germany), Embrapa (Brazil), Medix Biochemica (France), Miltenyi Biotec (Germany) and Absolute Antibody (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Recombinant DNA Technology market by , Application (Gene Therapy, Clinical Diagnosis, Insulin Production, Generate Antibody Probes and Others) and Region.



On the basis of geography, the market of Recombinant DNA Technology has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End users Industry, the sub-segment i.e. Agriculture will boost the Recombinant DNA Technology market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Technique, the sub-segment i.e. CRISPR-Cas9 will boost the Recombinant DNA Technology market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increased adoption of personalized medicine

Market Growth Drivers:
Rising prevalence of chronic diseases, Increasing demand of agricultural industry such as, improved yield, resistance to pests. and Growing advancements in gene editing technologies such as, CRISPR-Cas9

Challenges:
The use of recombinant DNA technology raises ethical considerations, particularly in the context of gene editing in humans

Restraints:
Mistrust or lack of awareness of genetically modified products and Developing and implementing recombinant DNA technologies can be costly.

Opportunities:
Developing advanced diagnostic methods and tools.

Market Leaders and their expansionary development strategies
In January 2022, Thermo Fischer scientific Inc., the world leader in serving science has acquired the peprotech, a leading developer and manufacturer of recombinant protein. The acquisition will be able to efficiently grow the business and generate attractive results furthering company’s Mission to enable the customers to make the world healthier, cleaner and safer.
In May 2021, Biogen, a discovers, develops and delivers worldwide innovative therapies for people announced collaboration with the Ginkgo, a biotechnology company which offers automated organism engineering, enzyme discovery and cultured fragrances. The companies aim to redefine the industry standard for manufacturing recombinant adeno-associated virus (AAV)-based vectors.


Key Target Audience
End users’ industry, Research Organization, Government Regulatory and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Gene Therapy
  • Clinical Diagnosis
  • Insulin Production
  • Generate Antibody Probes
  • Others
By End users Industry
  • Agriculture
  • Food Production
  • Human and Veterinary Medicine
  • Biotechnology
  • Pharmaceutical
  • Other

By Technique
  • CRISPR-Cas9
  • Polymerase Chain Reaction (PCR
  • DNA Sequencing
  • Gene Cloning

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising prevalence of chronic diseases
      • 3.2.2. Increasing demand of agricultural industry such as, improved yield, resistance to pests.
      • 3.2.3. Growing advancements in gene editing technologies such as, CRISPR-Cas9
    • 3.3. Market Challenges
      • 3.3.1. The use of recombinant DNA technology raises ethical considerations, particularly in the context of gene editing in humans
    • 3.4. Market Trends
      • 3.4.1. Increased adoption of personalized medicine
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Recombinant DNA Technology, by Application, End users Industry, Technique and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Recombinant DNA Technology (Value)
      • 5.2.1. Global Recombinant DNA Technology by: Application (Value)
        • 5.2.1.1. Gene Therapy
        • 5.2.1.2. Clinical Diagnosis
        • 5.2.1.3. Insulin Production
        • 5.2.1.4. Generate Antibody Probes
        • 5.2.1.5. Others
      • 5.2.2. Global Recombinant DNA Technology by: End users Industry (Value)
        • 5.2.2.1. Agriculture
        • 5.2.2.2. Food Production
        • 5.2.2.3. Human and Veterinary Medicine
        • 5.2.2.4. Biotechnology
        • 5.2.2.5. Pharmaceutical
        • 5.2.2.6. Other
      • 5.2.3. Global Recombinant DNA Technology by: Technique (Value)
        • 5.2.3.1. CRISPR-Cas9
        • 5.2.3.2. Polymerase Chain Reaction (PCR
        • 5.2.3.3. DNA Sequencing
        • 5.2.3.4. Gene Cloning
      • 5.2.4. Global Recombinant DNA Technology Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Recombinant DNA Technology: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Biogen (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Amgen Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Genentech, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. DAIICHI SANKYO COMPANY, LIMITED. (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. 4basebio (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Profacgen (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Astellas Pharma Inc. (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sanofi (France)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Pfizer Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Bioclone Inc. (Brazil)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. AstraZeneca (United Kingdom)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Takeda Pharmaceutical Company Limited (Japan)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. LenioBio (Germany)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. Embrapa (Brazil)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
      • 6.4.17. Medix Biochemica (France)
        • 6.4.17.1. Business Overview
        • 6.4.17.2. Products/Services Offerings
        • 6.4.17.3. Financial Analysis
        • 6.4.17.4. SWOT Analysis
      • 6.4.18. Miltenyi Biotec (Germany)
        • 6.4.18.1. Business Overview
        • 6.4.18.2. Products/Services Offerings
        • 6.4.18.3. Financial Analysis
        • 6.4.18.4. SWOT Analysis
      • 6.4.19. Absolute Antibody (United States)
        • 6.4.19.1. Business Overview
        • 6.4.19.2. Products/Services Offerings
        • 6.4.19.3. Financial Analysis
        • 6.4.19.4. SWOT Analysis
  • 7. Global Recombinant DNA Technology Sale, by Application, End users Industry, Technique and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Recombinant DNA Technology (Value)
      • 7.2.1. Global Recombinant DNA Technology by: Application (Value)
        • 7.2.1.1. Gene Therapy
        • 7.2.1.2. Clinical Diagnosis
        • 7.2.1.3. Insulin Production
        • 7.2.1.4. Generate Antibody Probes
        • 7.2.1.5. Others
      • 7.2.2. Global Recombinant DNA Technology by: End users Industry (Value)
        • 7.2.2.1. Agriculture
        • 7.2.2.2. Food Production
        • 7.2.2.3. Human and Veterinary Medicine
        • 7.2.2.4. Biotechnology
        • 7.2.2.5. Pharmaceutical
        • 7.2.2.6. Other
      • 7.2.3. Global Recombinant DNA Technology by: Technique (Value)
        • 7.2.3.1. CRISPR-Cas9
        • 7.2.3.2. Polymerase Chain Reaction (PCR
        • 7.2.3.3. DNA Sequencing
        • 7.2.3.4. Gene Cloning
      • 7.2.4. Global Recombinant DNA Technology Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Recombinant DNA Technology: by Application(USD Million)
  • Table 2. Recombinant DNA Technology Gene Therapy , by Region USD Million (2018-2023)
  • Table 3. Recombinant DNA Technology Clinical Diagnosis , by Region USD Million (2018-2023)
  • Table 4. Recombinant DNA Technology Insulin Production , by Region USD Million (2018-2023)
  • Table 5. Recombinant DNA Technology Generate Antibody Probes , by Region USD Million (2018-2023)
  • Table 6. Recombinant DNA Technology Others , by Region USD Million (2018-2023)
  • Table 7. Recombinant DNA Technology: by End users Industry(USD Million)
  • Table 8. Recombinant DNA Technology Agriculture , by Region USD Million (2018-2023)
  • Table 9. Recombinant DNA Technology Food Production , by Region USD Million (2018-2023)
  • Table 10. Recombinant DNA Technology Human and Veterinary Medicine , by Region USD Million (2018-2023)
  • Table 11. Recombinant DNA Technology Biotechnology , by Region USD Million (2018-2023)
  • Table 12. Recombinant DNA Technology Pharmaceutical , by Region USD Million (2018-2023)
  • Table 13. Recombinant DNA Technology Other , by Region USD Million (2018-2023)
  • Table 14. Recombinant DNA Technology: by Technique(USD Million)
  • Table 15. Recombinant DNA Technology CRISPR-Cas9 , by Region USD Million (2018-2023)
  • Table 16. Recombinant DNA Technology Polymerase Chain Reaction (PCR , by Region USD Million (2018-2023)
  • Table 17. Recombinant DNA Technology DNA Sequencing , by Region USD Million (2018-2023)
  • Table 18. Recombinant DNA Technology Gene Cloning , by Region USD Million (2018-2023)
  • Table 19. South America Recombinant DNA Technology, by Country USD Million (2018-2023)
  • Table 20. South America Recombinant DNA Technology, by Application USD Million (2018-2023)
  • Table 21. South America Recombinant DNA Technology, by End users Industry USD Million (2018-2023)
  • Table 22. South America Recombinant DNA Technology, by Technique USD Million (2018-2023)
  • Table 23. Brazil Recombinant DNA Technology, by Application USD Million (2018-2023)
  • Table 24. Brazil Recombinant DNA Technology, by End users Industry USD Million (2018-2023)
  • Table 25. Brazil Recombinant DNA Technology, by Technique USD Million (2018-2023)
  • Table 26. Argentina Recombinant DNA Technology, by Application USD Million (2018-2023)
  • Table 27. Argentina Recombinant DNA Technology, by End users Industry USD Million (2018-2023)
  • Table 28. Argentina Recombinant DNA Technology, by Technique USD Million (2018-2023)
  • Table 29. Rest of South America Recombinant DNA Technology, by Application USD Million (2018-2023)
  • Table 30. Rest of South America Recombinant DNA Technology, by End users Industry USD Million (2018-2023)
  • Table 31. Rest of South America Recombinant DNA Technology, by Technique USD Million (2018-2023)
  • Table 32. Asia Pacific Recombinant DNA Technology, by Country USD Million (2018-2023)
  • Table 33. Asia Pacific Recombinant DNA Technology, by Application USD Million (2018-2023)
  • Table 34. Asia Pacific Recombinant DNA Technology, by End users Industry USD Million (2018-2023)
  • Table 35. Asia Pacific Recombinant DNA Technology, by Technique USD Million (2018-2023)
  • Table 36. China Recombinant DNA Technology, by Application USD Million (2018-2023)
  • Table 37. China Recombinant DNA Technology, by End users Industry USD Million (2018-2023)
  • Table 38. China Recombinant DNA Technology, by Technique USD Million (2018-2023)
  • Table 39. Japan Recombinant DNA Technology, by Application USD Million (2018-2023)
  • Table 40. Japan Recombinant DNA Technology, by End users Industry USD Million (2018-2023)
  • Table 41. Japan Recombinant DNA Technology, by Technique USD Million (2018-2023)
  • Table 42. India Recombinant DNA Technology, by Application USD Million (2018-2023)
  • Table 43. India Recombinant DNA Technology, by End users Industry USD Million (2018-2023)
  • Table 44. India Recombinant DNA Technology, by Technique USD Million (2018-2023)
  • Table 45. South Korea Recombinant DNA Technology, by Application USD Million (2018-2023)
  • Table 46. South Korea Recombinant DNA Technology, by End users Industry USD Million (2018-2023)
  • Table 47. South Korea Recombinant DNA Technology, by Technique USD Million (2018-2023)
  • Table 48. Taiwan Recombinant DNA Technology, by Application USD Million (2018-2023)
  • Table 49. Taiwan Recombinant DNA Technology, by End users Industry USD Million (2018-2023)
  • Table 50. Taiwan Recombinant DNA Technology, by Technique USD Million (2018-2023)
  • Table 51. Australia Recombinant DNA Technology, by Application USD Million (2018-2023)
  • Table 52. Australia Recombinant DNA Technology, by End users Industry USD Million (2018-2023)
  • Table 53. Australia Recombinant DNA Technology, by Technique USD Million (2018-2023)
  • Table 54. Rest of Asia-Pacific Recombinant DNA Technology, by Application USD Million (2018-2023)
  • Table 55. Rest of Asia-Pacific Recombinant DNA Technology, by End users Industry USD Million (2018-2023)
  • Table 56. Rest of Asia-Pacific Recombinant DNA Technology, by Technique USD Million (2018-2023)
  • Table 57. Europe Recombinant DNA Technology, by Country USD Million (2018-2023)
  • Table 58. Europe Recombinant DNA Technology, by Application USD Million (2018-2023)
  • Table 59. Europe Recombinant DNA Technology, by End users Industry USD Million (2018-2023)
  • Table 60. Europe Recombinant DNA Technology, by Technique USD Million (2018-2023)
  • Table 61. Germany Recombinant DNA Technology, by Application USD Million (2018-2023)
  • Table 62. Germany Recombinant DNA Technology, by End users Industry USD Million (2018-2023)
  • Table 63. Germany Recombinant DNA Technology, by Technique USD Million (2018-2023)
  • Table 64. France Recombinant DNA Technology, by Application USD Million (2018-2023)
  • Table 65. France Recombinant DNA Technology, by End users Industry USD Million (2018-2023)
  • Table 66. France Recombinant DNA Technology, by Technique USD Million (2018-2023)
  • Table 67. Italy Recombinant DNA Technology, by Application USD Million (2018-2023)
  • Table 68. Italy Recombinant DNA Technology, by End users Industry USD Million (2018-2023)
  • Table 69. Italy Recombinant DNA Technology, by Technique USD Million (2018-2023)
  • Table 70. United Kingdom Recombinant DNA Technology, by Application USD Million (2018-2023)
  • Table 71. United Kingdom Recombinant DNA Technology, by End users Industry USD Million (2018-2023)
  • Table 72. United Kingdom Recombinant DNA Technology, by Technique USD Million (2018-2023)
  • Table 73. Netherlands Recombinant DNA Technology, by Application USD Million (2018-2023)
  • Table 74. Netherlands Recombinant DNA Technology, by End users Industry USD Million (2018-2023)
  • Table 75. Netherlands Recombinant DNA Technology, by Technique USD Million (2018-2023)
  • Table 76. Rest of Europe Recombinant DNA Technology, by Application USD Million (2018-2023)
  • Table 77. Rest of Europe Recombinant DNA Technology, by End users Industry USD Million (2018-2023)
  • Table 78. Rest of Europe Recombinant DNA Technology, by Technique USD Million (2018-2023)
  • Table 79. MEA Recombinant DNA Technology, by Country USD Million (2018-2023)
  • Table 80. MEA Recombinant DNA Technology, by Application USD Million (2018-2023)
  • Table 81. MEA Recombinant DNA Technology, by End users Industry USD Million (2018-2023)
  • Table 82. MEA Recombinant DNA Technology, by Technique USD Million (2018-2023)
  • Table 83. Middle East Recombinant DNA Technology, by Application USD Million (2018-2023)
  • Table 84. Middle East Recombinant DNA Technology, by End users Industry USD Million (2018-2023)
  • Table 85. Middle East Recombinant DNA Technology, by Technique USD Million (2018-2023)
  • Table 86. Africa Recombinant DNA Technology, by Application USD Million (2018-2023)
  • Table 87. Africa Recombinant DNA Technology, by End users Industry USD Million (2018-2023)
  • Table 88. Africa Recombinant DNA Technology, by Technique USD Million (2018-2023)
  • Table 89. North America Recombinant DNA Technology, by Country USD Million (2018-2023)
  • Table 90. North America Recombinant DNA Technology, by Application USD Million (2018-2023)
  • Table 91. North America Recombinant DNA Technology, by End users Industry USD Million (2018-2023)
  • Table 92. North America Recombinant DNA Technology, by Technique USD Million (2018-2023)
  • Table 93. United States Recombinant DNA Technology, by Application USD Million (2018-2023)
  • Table 94. United States Recombinant DNA Technology, by End users Industry USD Million (2018-2023)
  • Table 95. United States Recombinant DNA Technology, by Technique USD Million (2018-2023)
  • Table 96. Canada Recombinant DNA Technology, by Application USD Million (2018-2023)
  • Table 97. Canada Recombinant DNA Technology, by End users Industry USD Million (2018-2023)
  • Table 98. Canada Recombinant DNA Technology, by Technique USD Million (2018-2023)
  • Table 99. Mexico Recombinant DNA Technology, by Application USD Million (2018-2023)
  • Table 100. Mexico Recombinant DNA Technology, by End users Industry USD Million (2018-2023)
  • Table 101. Mexico Recombinant DNA Technology, by Technique USD Million (2018-2023)
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Company Basic Information, Sales Area and Its Competitors
  • Table 116. Company Basic Information, Sales Area and Its Competitors
  • Table 117. Company Basic Information, Sales Area and Its Competitors
  • Table 118. Company Basic Information, Sales Area and Its Competitors
  • Table 119. Company Basic Information, Sales Area and Its Competitors
  • Table 120. Company Basic Information, Sales Area and Its Competitors
  • Table 121. Recombinant DNA Technology: by Application(USD Million)
  • Table 122. Recombinant DNA Technology Gene Therapy , by Region USD Million (2025-2030)
  • Table 123. Recombinant DNA Technology Clinical Diagnosis , by Region USD Million (2025-2030)
  • Table 124. Recombinant DNA Technology Insulin Production , by Region USD Million (2025-2030)
  • Table 125. Recombinant DNA Technology Generate Antibody Probes , by Region USD Million (2025-2030)
  • Table 126. Recombinant DNA Technology Others , by Region USD Million (2025-2030)
  • Table 127. Recombinant DNA Technology: by End users Industry(USD Million)
  • Table 128. Recombinant DNA Technology Agriculture , by Region USD Million (2025-2030)
  • Table 129. Recombinant DNA Technology Food Production , by Region USD Million (2025-2030)
  • Table 130. Recombinant DNA Technology Human and Veterinary Medicine , by Region USD Million (2025-2030)
  • Table 131. Recombinant DNA Technology Biotechnology , by Region USD Million (2025-2030)
  • Table 132. Recombinant DNA Technology Pharmaceutical , by Region USD Million (2025-2030)
  • Table 133. Recombinant DNA Technology Other , by Region USD Million (2025-2030)
  • Table 134. Recombinant DNA Technology: by Technique(USD Million)
  • Table 135. Recombinant DNA Technology CRISPR-Cas9 , by Region USD Million (2025-2030)
  • Table 136. Recombinant DNA Technology Polymerase Chain Reaction (PCR , by Region USD Million (2025-2030)
  • Table 137. Recombinant DNA Technology DNA Sequencing , by Region USD Million (2025-2030)
  • Table 138. Recombinant DNA Technology Gene Cloning , by Region USD Million (2025-2030)
  • Table 139. South America Recombinant DNA Technology, by Country USD Million (2025-2030)
  • Table 140. South America Recombinant DNA Technology, by Application USD Million (2025-2030)
  • Table 141. South America Recombinant DNA Technology, by End users Industry USD Million (2025-2030)
  • Table 142. South America Recombinant DNA Technology, by Technique USD Million (2025-2030)
  • Table 143. Brazil Recombinant DNA Technology, by Application USD Million (2025-2030)
  • Table 144. Brazil Recombinant DNA Technology, by End users Industry USD Million (2025-2030)
  • Table 145. Brazil Recombinant DNA Technology, by Technique USD Million (2025-2030)
  • Table 146. Argentina Recombinant DNA Technology, by Application USD Million (2025-2030)
  • Table 147. Argentina Recombinant DNA Technology, by End users Industry USD Million (2025-2030)
  • Table 148. Argentina Recombinant DNA Technology, by Technique USD Million (2025-2030)
  • Table 149. Rest of South America Recombinant DNA Technology, by Application USD Million (2025-2030)
  • Table 150. Rest of South America Recombinant DNA Technology, by End users Industry USD Million (2025-2030)
  • Table 151. Rest of South America Recombinant DNA Technology, by Technique USD Million (2025-2030)
  • Table 152. Asia Pacific Recombinant DNA Technology, by Country USD Million (2025-2030)
  • Table 153. Asia Pacific Recombinant DNA Technology, by Application USD Million (2025-2030)
  • Table 154. Asia Pacific Recombinant DNA Technology, by End users Industry USD Million (2025-2030)
  • Table 155. Asia Pacific Recombinant DNA Technology, by Technique USD Million (2025-2030)
  • Table 156. China Recombinant DNA Technology, by Application USD Million (2025-2030)
  • Table 157. China Recombinant DNA Technology, by End users Industry USD Million (2025-2030)
  • Table 158. China Recombinant DNA Technology, by Technique USD Million (2025-2030)
  • Table 159. Japan Recombinant DNA Technology, by Application USD Million (2025-2030)
  • Table 160. Japan Recombinant DNA Technology, by End users Industry USD Million (2025-2030)
  • Table 161. Japan Recombinant DNA Technology, by Technique USD Million (2025-2030)
  • Table 162. India Recombinant DNA Technology, by Application USD Million (2025-2030)
  • Table 163. India Recombinant DNA Technology, by End users Industry USD Million (2025-2030)
  • Table 164. India Recombinant DNA Technology, by Technique USD Million (2025-2030)
  • Table 165. South Korea Recombinant DNA Technology, by Application USD Million (2025-2030)
  • Table 166. South Korea Recombinant DNA Technology, by End users Industry USD Million (2025-2030)
  • Table 167. South Korea Recombinant DNA Technology, by Technique USD Million (2025-2030)
  • Table 168. Taiwan Recombinant DNA Technology, by Application USD Million (2025-2030)
  • Table 169. Taiwan Recombinant DNA Technology, by End users Industry USD Million (2025-2030)
  • Table 170. Taiwan Recombinant DNA Technology, by Technique USD Million (2025-2030)
  • Table 171. Australia Recombinant DNA Technology, by Application USD Million (2025-2030)
  • Table 172. Australia Recombinant DNA Technology, by End users Industry USD Million (2025-2030)
  • Table 173. Australia Recombinant DNA Technology, by Technique USD Million (2025-2030)
  • Table 174. Rest of Asia-Pacific Recombinant DNA Technology, by Application USD Million (2025-2030)
  • Table 175. Rest of Asia-Pacific Recombinant DNA Technology, by End users Industry USD Million (2025-2030)
  • Table 176. Rest of Asia-Pacific Recombinant DNA Technology, by Technique USD Million (2025-2030)
  • Table 177. Europe Recombinant DNA Technology, by Country USD Million (2025-2030)
  • Table 178. Europe Recombinant DNA Technology, by Application USD Million (2025-2030)
  • Table 179. Europe Recombinant DNA Technology, by End users Industry USD Million (2025-2030)
  • Table 180. Europe Recombinant DNA Technology, by Technique USD Million (2025-2030)
  • Table 181. Germany Recombinant DNA Technology, by Application USD Million (2025-2030)
  • Table 182. Germany Recombinant DNA Technology, by End users Industry USD Million (2025-2030)
  • Table 183. Germany Recombinant DNA Technology, by Technique USD Million (2025-2030)
  • Table 184. France Recombinant DNA Technology, by Application USD Million (2025-2030)
  • Table 185. France Recombinant DNA Technology, by End users Industry USD Million (2025-2030)
  • Table 186. France Recombinant DNA Technology, by Technique USD Million (2025-2030)
  • Table 187. Italy Recombinant DNA Technology, by Application USD Million (2025-2030)
  • Table 188. Italy Recombinant DNA Technology, by End users Industry USD Million (2025-2030)
  • Table 189. Italy Recombinant DNA Technology, by Technique USD Million (2025-2030)
  • Table 190. United Kingdom Recombinant DNA Technology, by Application USD Million (2025-2030)
  • Table 191. United Kingdom Recombinant DNA Technology, by End users Industry USD Million (2025-2030)
  • Table 192. United Kingdom Recombinant DNA Technology, by Technique USD Million (2025-2030)
  • Table 193. Netherlands Recombinant DNA Technology, by Application USD Million (2025-2030)
  • Table 194. Netherlands Recombinant DNA Technology, by End users Industry USD Million (2025-2030)
  • Table 195. Netherlands Recombinant DNA Technology, by Technique USD Million (2025-2030)
  • Table 196. Rest of Europe Recombinant DNA Technology, by Application USD Million (2025-2030)
  • Table 197. Rest of Europe Recombinant DNA Technology, by End users Industry USD Million (2025-2030)
  • Table 198. Rest of Europe Recombinant DNA Technology, by Technique USD Million (2025-2030)
  • Table 199. MEA Recombinant DNA Technology, by Country USD Million (2025-2030)
  • Table 200. MEA Recombinant DNA Technology, by Application USD Million (2025-2030)
  • Table 201. MEA Recombinant DNA Technology, by End users Industry USD Million (2025-2030)
  • Table 202. MEA Recombinant DNA Technology, by Technique USD Million (2025-2030)
  • Table 203. Middle East Recombinant DNA Technology, by Application USD Million (2025-2030)
  • Table 204. Middle East Recombinant DNA Technology, by End users Industry USD Million (2025-2030)
  • Table 205. Middle East Recombinant DNA Technology, by Technique USD Million (2025-2030)
  • Table 206. Africa Recombinant DNA Technology, by Application USD Million (2025-2030)
  • Table 207. Africa Recombinant DNA Technology, by End users Industry USD Million (2025-2030)
  • Table 208. Africa Recombinant DNA Technology, by Technique USD Million (2025-2030)
  • Table 209. North America Recombinant DNA Technology, by Country USD Million (2025-2030)
  • Table 210. North America Recombinant DNA Technology, by Application USD Million (2025-2030)
  • Table 211. North America Recombinant DNA Technology, by End users Industry USD Million (2025-2030)
  • Table 212. North America Recombinant DNA Technology, by Technique USD Million (2025-2030)
  • Table 213. United States Recombinant DNA Technology, by Application USD Million (2025-2030)
  • Table 214. United States Recombinant DNA Technology, by End users Industry USD Million (2025-2030)
  • Table 215. United States Recombinant DNA Technology, by Technique USD Million (2025-2030)
  • Table 216. Canada Recombinant DNA Technology, by Application USD Million (2025-2030)
  • Table 217. Canada Recombinant DNA Technology, by End users Industry USD Million (2025-2030)
  • Table 218. Canada Recombinant DNA Technology, by Technique USD Million (2025-2030)
  • Table 219. Mexico Recombinant DNA Technology, by Application USD Million (2025-2030)
  • Table 220. Mexico Recombinant DNA Technology, by End users Industry USD Million (2025-2030)
  • Table 221. Mexico Recombinant DNA Technology, by Technique USD Million (2025-2030)
  • Table 222. Research Programs/Design for This Report
  • Table 223. Key Data Information from Secondary Sources
  • Table 224. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Recombinant DNA Technology: by Application USD Million (2018-2023)
  • Figure 5. Global Recombinant DNA Technology: by End users Industry USD Million (2018-2023)
  • Figure 6. Global Recombinant DNA Technology: by Technique USD Million (2018-2023)
  • Figure 7. South America Recombinant DNA Technology Share (%), by Country
  • Figure 8. Asia Pacific Recombinant DNA Technology Share (%), by Country
  • Figure 9. Europe Recombinant DNA Technology Share (%), by Country
  • Figure 10. MEA Recombinant DNA Technology Share (%), by Country
  • Figure 11. North America Recombinant DNA Technology Share (%), by Country
  • Figure 12. Global Recombinant DNA Technology share by Players 2023 (%)
  • Figure 13. Global Recombinant DNA Technology share by Players (Top 3) 2023(%)
  • Figure 14. Global Recombinant DNA Technology share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 17. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2023
  • Figure 18. Biogen (United States) Revenue, Net Income and Gross profit
  • Figure 19. Biogen (United States) Revenue: by Geography 2023
  • Figure 20. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Amgen Inc. (United States) Revenue: by Geography 2023
  • Figure 22. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 23. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 24. Genentech, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Genentech, Inc. (United States) Revenue: by Geography 2023
  • Figure 26. DAIICHI SANKYO COMPANY, LIMITED. (Japan) Revenue, Net Income and Gross profit
  • Figure 27. DAIICHI SANKYO COMPANY, LIMITED. (Japan) Revenue: by Geography 2023
  • Figure 28. 4basebio (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. 4basebio (United Kingdom) Revenue: by Geography 2023
  • Figure 30. Profacgen (United States) Revenue, Net Income and Gross profit
  • Figure 31. Profacgen (United States) Revenue: by Geography 2023
  • Figure 32. Astellas Pharma Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 33. Astellas Pharma Inc. (Japan) Revenue: by Geography 2023
  • Figure 34. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 35. Sanofi (France) Revenue: by Geography 2023
  • Figure 36. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 38. Bioclone Inc. (Brazil) Revenue, Net Income and Gross profit
  • Figure 39. Bioclone Inc. (Brazil) Revenue: by Geography 2023
  • Figure 40. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 41. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 42. Takeda Pharmaceutical Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 43. Takeda Pharmaceutical Company Limited (Japan) Revenue: by Geography 2023
  • Figure 44. LenioBio (Germany) Revenue, Net Income and Gross profit
  • Figure 45. LenioBio (Germany) Revenue: by Geography 2023
  • Figure 46. Embrapa (Brazil) Revenue, Net Income and Gross profit
  • Figure 47. Embrapa (Brazil) Revenue: by Geography 2023
  • Figure 48. Medix Biochemica (France) Revenue, Net Income and Gross profit
  • Figure 49. Medix Biochemica (France) Revenue: by Geography 2023
  • Figure 50. Miltenyi Biotec (Germany) Revenue, Net Income and Gross profit
  • Figure 51. Miltenyi Biotec (Germany) Revenue: by Geography 2023
  • Figure 52. Absolute Antibody (United States) Revenue, Net Income and Gross profit
  • Figure 53. Absolute Antibody (United States) Revenue: by Geography 2023
  • Figure 54. Global Recombinant DNA Technology: by Application USD Million (2025-2030)
  • Figure 55. Global Recombinant DNA Technology: by End users Industry USD Million (2025-2030)
  • Figure 56. Global Recombinant DNA Technology: by Technique USD Million (2025-2030)
  • Figure 57. South America Recombinant DNA Technology Share (%), by Country
  • Figure 58. Asia Pacific Recombinant DNA Technology Share (%), by Country
  • Figure 59. Europe Recombinant DNA Technology Share (%), by Country
  • Figure 60. MEA Recombinant DNA Technology Share (%), by Country
  • Figure 61. North America Recombinant DNA Technology Share (%), by Country
List of companies from research coverage that are profiled in the study
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Biogen (United States)
  • Amgen Inc. (United States)
  • Novartis AG (Switzerland)
  • Genentech, Inc. (United States)
  • DAIICHI SANKYO COMPANY, LIMITED. (Japan)
  • 4basebio (United Kingdom)
  • Profacgen (United States)
  • Astellas Pharma Inc. (Japan)
  • Sanofi (France)
  • Pfizer Inc. (United States)
  • Bioclone Inc. (Brazil)
  • AstraZeneca (United Kingdom)
  • Takeda Pharmaceutical Company Limited (Japan)
  • LenioBio (Germany)
  • Embrapa (Brazil)
  • Medix Biochemica (France)
  • Miltenyi Biotec (Germany)
  • Absolute Antibody (United States)
Select User Access Type

Key Highlights of Report


Feb 2024 240 Pages 53 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Recombinant DNA Technology Quantitative research analysis
Global Recombinant DNA Technology Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as F. Hoffmann-La Roche Ltd (Switzerland), Biogen (United States), Amgen Inc. (United States), Novartis AG (Switzerland), Genentech, Inc. (United States), DAIICHI SANKYO COMPANY, LIMITED. (Japan), 4basebio (United Kingdom), Profacgen (United States), Astellas Pharma Inc. (Japan), Sanofi (France), Pfizer Inc. (United States), Bioclone Inc. (Brazil), AstraZeneca (United Kingdom), Takeda Pharmaceutical Company Limited (Japan), LenioBio (Germany), Embrapa (Brazil), Medix Biochemica (France), Miltenyi Biotec (Germany) and Absolute Antibody (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increased adoption of personalized medicine" is seen as one of major influencing trends for Recombinant DNA Technology Market during projected period 2023-2030.
The Recombinant DNA Technology market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Recombinant DNA Technology Report?

Have a Query? Click Here

Other Related Reports

Viral Vector Manufacturing Comprehensive Study by Type (Retroviruses, Lentiviruses, Adenoviruses, Adeno-associated viruses, Plant viruses, Hybrids, Others), Application (Research, Gene Therapy, Vacci...
$ 3450
ChIP-on-chip Comprehensive Study by Type (Chromatin Immunoprecipitation Sequencing Kits, Chromatin Immunoprecipitation Sequencing Array), Application (Gene Expression, Genotyping, Genome Cytogenetics...
$ 3750
High Content Screening Comprehensive Study by Type (Instruments (Cell Imaging and Analysis Systems, Flow Cytometers), Consumables (Reagents and Assay Kits, Micro plates, other), Software, Services, A...
$ 3750
Microbiology Testing Comprehensive Study by Type (Instruments, Reagents), Application (Pharmaceutical, Clinical, Food Testing, Energy, Chemical and Material Manufacturing, Environment), Disease Area ...
$ 3650
Gene Gun Comprehensive Study by Type (Desktop Type, Handhold Type, Other), Application (Agriculture, Medical, Others) Players and Region - Global Market Outlook to 2030
$ 3500
Biologic Drugs Comprehensive Study by Type (Vaccines, Blood and Blood Components, Allergenics, Somatic Cells, Gene Therapy, Tissues, Recombinant Therapeutic Proteins), Application (Cancer, Rheumatoid...
$ 3650